GlassScriptPhysician profile
Robert Malachi Mccurdy
NPI 1598109514
$38,074.75
in general payments reported to CMS, 2019-2025
22 companies · $8,763 in 2025
The $8,763 reported for 2025 was more than what 94% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $31.50 · 2021: $92.91 · 2022: $20K · 2023: $338 · 2024: $8,662 · 2025: $8,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $16K · Food and Beverage: $1,648 · Travel and Lodging: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $16,000.00 |
| Food and Beverage | $1,647.82 |
| Travel and Lodging | $116.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $34,191.65 | 2019-2025 | |
| Zimmer Biomet Holdings, INC. | $2,718.94 | 2022 | |
| Davol INC. | $394.34 | 2019-2024 | Phasix Mesh |
| Becton, Dickinson and Company | $151.28 | 2019-2025 | Phasix Mesh |
| Medtronic, INC. | $141.89 | 2021-2025 | Endoflip |
| Boston Scientific Corporation | $59.48 | 2021 | |
| Tela Bio, INC. | $55.55 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Polynovo North America LLC | $45.94 | 2023 | |
| Misonix INC | $43.93 | 2019 | |
| Kci USA, INC. | $38.50 | 2023 | Activ.A.C. Ion Progress, V.A.C. Dermatac, Prevena |
| Avanos Medical | $36.49 | 2024 | Peg, Entral |
| Solventum Corporation | $36.47 | 2024-2025 | Prevena, V.A.C.Ulta, V.A.C. Veraflo Cleanse Choice |
| Integra Lifesciences Corporation | $30.08 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $20.88 | 2023 | Exparel |
| Shire North American Group INC | $16.27 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $15.81 | 2024 | Xerava |
| Phathom Pharmaceuticals, INC. | $15.29 | 2025 | Voquezna |
| Baudax Bio INC. | $14.91 | 2021 | |
| Puma Biotechnology, INC. | $14.10 | 2024 | |
| Medtronic Vascular, INC. | $13.33 | 2020 | |
| Z-Medica, LLC | $10.31 | 2019 | |
| Kerecis Limited | $9.31 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mccurdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.